Suchen
Virax Biolabs Group Ltd
VRAXZur Watchlist hinzufügen
3.130USD
+0.390+14.23%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
13.59MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Virax Biolabs Group Ltd Unternehmen
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Virax Biolabs Group Ltd Informationen
BörsenkürzelVRAX
Name des UnternehmensVirax Biolabs Group Ltd
IPO-datumJul 14, 2022
CEOFoster (James)
Anzahl der mitarbeiter19
WertpapierartOrdinary Share
GeschäftsjahresendeJul 14
AddresseBiocity Glasgow
StadtLONDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlML1 5UH
Telefon4402077887414
Websitehttps://www.viraxbiolabs.com
BörsenkürzelVRAX
IPO-datumJul 14, 2022
CEOFoster (James)
Führungskräfte von Virax Biolabs Group Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
11.52K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
613.00
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
11.52K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
613.00
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Virax Biolabs Group Ltd?
Die fünf größten Anteilseigner von Virax Biolabs Group Ltd sind: Mr. James Foster
Wie viele Institutionen halten Anteile an Virax Biolabs Group Ltd (VRAX)?
Mit Stand vom 2026Q1 halten 22 Institutionen Anteile an Virax Biolabs Group Ltd, mit einem Gesamtmarktwert von etwa 851.39K, was 4.27% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 268600.00 gestiegen.